UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 19, 2003
| La Jolla Pharmaceutical Company |
| (Exact Name of Registrant as Specified in Charter) |
| Delaware | 0-24274 | 33-0361285 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6455 Nancy Ridge Drive, San Diego, California | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
| N/A |
| (Former Name or Former Address, if Changed Since Last Report) |
| Item 5. Other Events and Required FD Disclosure. | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events and Required FD Disclosure.
On June 19, 2003, the Company issued a press release announcing that Dr. Mario Cardiel, one of the Company’s principal investigators, reviewed previously released data from the Company's Phase 3 trial of Riquent™ at the EULAR Conference on June 19, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits are filed with this report on Form 8-K:
| Exhibit | ||
| Number | Description of Exhibit | |
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY | ||||
| Date: June 19, 2003 | By: | /s/ Gail A. Sloan | ||
| Gail A. Sloan Senior Director of Finance, Controller and Secretary |
||||
EXHIBIT INDEX
| Exhibit | ||
| Number | Description of Exhibit | |
| 99.1 | Press Release |